SEZI Stock Overview A medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Senzime AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Senzime Historical stock prices Current Share Price SEK 5.80 52 Week High SEK 9.60 52 Week Low SEK 5.44 Beta 0.57 1 Month Change 1.58% 3 Month Change -2.19% 1 Year Change -15.58% 3 Year Change -71.98% 5 Year Change -66.38% Change since IPO -32.56%
Recent News & Updates
New minor risk - Shareholder dilution Dec 03
Chairman of the Board recently bought kr514k worth of stock Nov 27
New minor risk - Profitability Nov 13
Chairman of the Board recently bought kr163k worth of stock Nov 11
Chairman of the Board recently bought kr163k worth of stock Nov 10
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 07 See more updates
New minor risk - Shareholder dilution Dec 03
Chairman of the Board recently bought kr514k worth of stock Nov 27
New minor risk - Profitability Nov 13
Chairman of the Board recently bought kr163k worth of stock Nov 11
Chairman of the Board recently bought kr163k worth of stock Nov 10
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 07 Senzime AB (publ) to Report Q1, 2025 Results on May 07, 2025
Senzime Successfully Unveils Next-Generation TetraGraph Quantitative Train-Of-Four Monitor at ANESTHESI Technology 2024 Oct 29
Senzime to Launch Next-Generation Tetragraph System At Anesthesiology 2024 Conference Oct 15
Second quarter 2024 earnings: Revenues miss analyst expectations Aug 27
Senzime AB (publ.) Announces European Patent Office Issues New Patent Protecting Unique Capabilities of the Senzime TetraGraph System Jun 25
New minor risk - Profitability May 14
New minor risk - Financial position May 07
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 29
Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024 Feb 20
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 18
Less than half of directors are independent Dec 07
Senzime AB (publ) Announces Board Changes Nov 29
Chief Financial Officer recently bought kr67k worth of stock Nov 09
Chief Financial Officer recently bought kr67k worth of stock Nov 09
Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open Nov 09 Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 27
New major risk - Shareholder dilution Oct 26
Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin Oct 10
New major risk - Financial position Aug 25
Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor Jul 04
Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm Jun 06
Less than half of directors are independent May 11
Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer May 05
First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022) Apr 30
Independent Chairman recently bought kr740k worth of stock Mar 29
Senzime Receives Approval for Its Pediatric Sensor in Japan Feb 10
Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021) Feb 02 Senzime AB (publ) to Report Q1, 2023 Results on May 05, 2023
Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023 Jan 24
Senzime Receives First Contract for TetraSens Pediatric in the US Dec 08
Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring Nov 17
Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021) Nov 16
Less than half of directors are independent Nov 16
Senzime AB (publ) Provides Earnings Guidance for 2025 Nov 16
Third quarter 2022 earnings released: kr0.74 loss per share (vs kr0.31 loss in 3Q 2021) Nov 12
Senzime AB (Publ) Announces Board Appointments Sep 01
Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children Aug 18
Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records Aug 06
Consensus revenue estimates fall by 34% Jul 22
Forecast breakeven date pushed back to 2024 Jul 19
Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021) Jul 16 Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million. Jun 02
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
Price target decreased to kr34.00 Apr 27
Less than half of directors are independent Apr 27
Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children Feb 24
Will Senzime (STO:SEZI) Spend Its Cash Wisely? Feb 20
Price target decreased to kr34.00 Feb 19
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 18
Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered Feb 06
Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX Jan 28
Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020) Nov 13
We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth Sep 01
Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020) Aug 28
Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth May 18
First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020) May 08
How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own? Mar 15
Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors Mar 07
Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019) Feb 28 Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021
New 90-day low: kr21.50 Feb 24
Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return Feb 16
We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely Jan 19
New 90-day high: kr25.80 Jan 04
Senzime AB (publ) Gets US Patent for OnZurf Probe Dec 25
Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock? Dec 23
Senzime Lands New Order from South Korea of SEK 1 Million Nov 26
What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)? Nov 26
Third quarter 2020 earnings released: kr0.20 loss per share Nov 12
Senzime AB (publ) Announces Nomination Committee for 2021 Annual General Meeting Nov 05
Senzime AB (Publ) Signs an Out-Licensing Agreement with the Moss S.P.A Nov 03
Senzime AB (publ) Enters into an Exclusive Agreement with the Surgical Company Oct 30
New 90-day low: kr19.70 Oct 27
Senzime AB (Publ) Announces Management Changes Oct 19
Senzime AB (publ) Receives Order from Switzerland Oct 04
New 90-day high: kr26.30 Sep 22 Shareholder Returns SEZI SE Medical Equipment SE Market 7D 0% 0.4% -2.7% 1Y -15.6% -8.1% 4.6%
See full shareholder returns
Return vs Market: SEZI underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility Is SEZI's price volatile compared to industry and market? SEZI volatility SEZI Average Weekly Movement 6.1% Medical Equipment Industry Average Movement 6.9% Market Average Movement 5.6% 10% most volatile stocks in SE Market 11.3% 10% least volatile stocks in SE Market 3.2%
Stable Share Price: SEZI has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: SEZI's weekly volatility (6%) has been stable over the past year.
About the Company Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategic connectivity and licensing agreement with Masimo to develop, manufacture, market, and distribute products that can connect to the Masimo Root patient monitoring system and related digital hub for data transmission to hospital electronic patient journals; license agreement with Fukuda Denshi Co. Ltd.
Show more Senzime AB (publ) Fundamentals Summary How do Senzime's earnings and revenue compare to its market cap? SEZI fundamental statistics Market cap SEK 768.35m Earnings (TTM ) -SEK 131.46m Revenue (TTM ) SEK 55.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SEZI income statement (TTM ) Revenue SEK 55.29m Cost of Revenue SEK 36.90m Gross Profit SEK 18.40m Other Expenses SEK 149.86m Earnings -SEK 131.46m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 17, 2025
Earnings per share (EPS) -0.99 Gross Margin 33.27% Net Profit Margin -237.75% Debt/Equity Ratio 0%
How did SEZI perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:08 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Senzime AB (publ) is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Klas Palin Carnegie Commissioned Research Oscar Stjerngren Danske Bank Klas Palin Penser Access
Show 0 more analysts 
